Zydus Lifesciences Limited
ZYDUSLIFE
Rangering i aksjer
#1743
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Aksjekurs
$12.30
Sist synkronisert: 2026-10-21
Markedsverdi
$12.27B
Endring (1 dag)
0.06%
Endring (1 år)
8.33%
Land
IN
Handel Zydus Lifesciences Limited (ZYDUSLIFE)
Kategori
Healthcare
Antall utestående aksjer for Zydus Lifesciences Limited (ZYDUSLIFE)
Antall utestående aksjer per June 2026: 1.01B
Ifølge Zydus Lifesciences Limited sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 1.01B. Ved slutten av March 2024 hadde selskapet 1.01B utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Zydus Lifesciences Limited (ZYDUSLIFE) fra 2004 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 1.01B | -0.12% |
| 2025 | 1.01B | -0.55% |
| 2024 | 1.01B | -0.37% |
| 2023 | 1.02B | -0.79% |
| 2022 | 1.02B | 0.00% |
| 2021 | 1.02B | 0.00% |
| 2020 | 1.02B | 0.00% |
| 2019 | 1.02B | 0.00% |
| 2018 | 1.02B | 0.00% |
| 2017 | 1.02B | 0.00% |
| 2016 | 1.02B | 0.00% |
| 2015 | 1.02B | 0.00% |
| 2014 | 1.02B | 0.00% |
| 2013 | 1.02B | 0.00% |
| 2012 | 1.02B | 0.00% |
| 2011 | 1.02B | 0.00% |
| 2010 | 1.02B | 0.00% |
| 2009 | 1.02B | 8.67% |
| 2008 | 942.10M | 0.00% |
| 2007 | 942.10M | 0.00% |
| 2006 | 942.10M | 100.00% |
| 2005 | 471.05M | 0.00% |
| 2004 | 471.05M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 138.71% |
IN
|
